Burosumab
Based on 1 publication(s) in Google Scholar
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.20%
- CAS No.: 1610833-03-8
- 분자량:144.08 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Burosumab
More
Biological Activity
Human IgG1(D356E/L358M) kappa
Human
FGF23
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4-week-old male Hyp mice (C57BL/6J background) with X-linked hypophosphatemia caused by PHEX gene mutation[3]
-
Dosage:4 and 16 mg/kg
-
Administration:Subcutaneous injection; once weekly; 2 months
-
Result:Significantly improved dentin/cementum volume, reduced pulp chamber volume to wild-type levels, particularly with 16 mg/kg.
Enhanced alveolar bone volume fraction and mineral density, restored periodontal ligament attachment and acellular cementum continuity.
Decreased osteoid and cementoid accumulation.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized FGF23-N-His can bind Burosumab. The EC50 for this effect is 241 ng/mL.
Chemical Information
-
CAS No. 1610833-03-8
-
Appearance Liquid
-
분자량 144.08 kDa
-
Color Colorless to light yellow
-
SMILES
[Burosumab]
-
Synonyms
KRN23; N5KG1_C10_LH; UX-023
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biology (Basel)
FGF23 Controls Myocardial Fibrosis Progression via Promoting Cardiac Fibroblast Proliferation and Activation in Mice. [Abstract]2026 Mar 27;15(7):539. PMID: 41972542
순도&문서
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Schindeler A, et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. Front Endocrinol (Lausanne). 2020 May 28;11:338. [Content Brief]
[2]. Colangelo L, et al. Appropriate dosing of burosumab in tumor-induced osteomalacia. Osteoporos Int. 2022 Dec 1. [Content Brief]
[3]. Lira Dos Santos EJ, et al. Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia. Int J Oral Sci. 2023 Dec 6;15(1):53. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Burosumab Related Classifications
HY-P9939 Related Classifications
Powered by Bioz